MCID: VRL010
MIFTS: 60

Viral Hepatitis

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Viral Hepatitis

MalaCards integrated aliases for Viral Hepatitis:

Name: Viral Hepatitis 12 55 3 15 73
Hepatitis, Viral, Animal 44 73
Viral Hepatitis with Hepatic Coma 12
Animal Viral Hepatitis 12
Human Viral Hepatitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1884
MeSH 44 D006524

Summaries for Viral Hepatitis

Disease Ontology : 12 A hepatitis that involves viral infection causing inflammation of the liver.

MalaCards based summary : Viral Hepatitis, also known as hepatitis, viral, animal, is related to non-a-e hepatitis and hepatitis a. An important gene associated with Viral Hepatitis is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are Human cytomegalovirus infection and Toll-like Receptor Signaling Pathway. The drugs Peginterferon alfa-2a and Peginterferon alfa-2b have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and t cells, and related phenotypes are Reduced mammosphere formation and homeostasis/metabolism

CDC : 3 Get hepatitis email updates

Wikipedia : 76 Viral hepatitis is liver inflammation due to a viral infection. It may present in acute form as a recent... more...

Related Diseases for Viral Hepatitis

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Viral Hepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 268)
# Related Disease Score Top Affiliating Genes
1 non-a-e hepatitis 32.7 ALB F2
2 hepatitis a 32.5 ABCB7 AFP ALB F2 GPT SEPSECS
3 hepatitis c 32.1 GGT1 GPT IFNA1 IFNA2 KRT18 TNF
4 epstein-barr virus hepatitis 31.9 ALB F2
5 hepatitis d 31.6 F2 GPT IFNA2
6 hepatitis e 30.8 ALB F2 GPT TNF
7 hepatitis 30.7 AFP F2 FASLG GGT1 GPT IFNA1
8 acute liver failure 30.7 ALB F2 GPT SLC17A5
9 hepatitis b 30.6 AFP ALB F2 FGL2 GGT1 GPT
10 hepatic coma 30.6 ALB F2 GPT
11 infantile liver failure syndrome 1 30.6 ALB F2 GPT SLC17A5
12 fatty liver disease 30.4 FAS GGT1 SLC17A5 TNF
13 human immunodeficiency virus infectious disease 30.4 IFNA1 TLR9 TNF
14 hepatocellular carcinoma 30.4 AFP ALB F2 FASLG GGT1 HFE
15 typhoid fever 30.4 ALB F2 TNF
16 schistosomiasis 30.1 ALB F2 TNF
17 alcohol abuse 30.1 ABCB7 GGT1 GPT SLC17A5
18 autoimmune hepatitis 30.0 F2 FAS GGT1 GPT SEPSECS
19 guillain-barre syndrome 30.0 ALB FAS TNF
20 viral infectious disease 29.9 GPT IFNA1 IFNA2 MX1 TLR9 TNF
21 alcoholic liver cirrhosis 29.9 AFP ALB F2 SLC17A5
22 aplastic anemia 29.9 ALB FAS FASLG HFE TNF
23 protein-energy malnutrition 29.8 ALB GPT TNF
24 opisthorchiasis 29.8 AFP GPT TNF
25 lichen planus 29.8 MX1 TLR9 TNF
26 fatty liver disease, nonalcoholic 1 29.7 GPT KRT18 SLC17A5
27 portal hypertension 29.7 ALB F2 GPT TNF
28 alpha-1-antitrypsin deficiency 29.7 ALB HFE SERPINA1
29 graft-versus-host disease 29.6 FAS FASLG TNF
30 arteries, anomalies of 29.6 ALB TLR9 TNF
31 hepatic encephalopathy 29.6 ALB F2 GPT SLC17A5 TNF
32 scrub typhus 29.6 GPT SLC17A5 TLR2 TNF
33 bilirubin metabolic disorder 29.6 ALB F2 GGT1 GPT SLC17A5
34 toxoplasmosis 29.5 TLR2 TLR9 TNF
35 primary biliary cirrhosis 29.5 ALB F2 GGT1 SEPSECS
36 alcoholic hepatitis 29.4 ALB F2 GPT KRT18 SLC17A5 TNF
37 cholecystitis 29.4 ALB F2 GPT KRT18
38 liver cirrhosis 29.3 AFP ALB F2 GGT1 GPT HFE
39 diabetes mellitus, noninsulin-dependent 29.2 ALB GGT1 GPT SLC17A5 TNF
40 nonalcoholic steatohepatitis 29.1 F2 GPT HFE KRT18 SLC17A5 TNF
41 gastrointestinal system disease 29.0 AFP ALB F2 GGT1 IFNA1 SERPINA1
42 malaria 29.0 ALB FASLG TLR2 TLR9 TNF
43 liver disease 28.9 ABCB7 AFP ALB F2 FAS GGT1
44 fulminant viral hepatitis 12.3
45 porphyria cutanea tarda 11.3
46 australia antigen 10.5
47 paraquat poisoning 10.3 GPT SLC17A5
48 lymphomatoid granulomatosis 10.3 IFNA1 IFNA2
49 antipyrine metabolism 10.3 ALB F2
50 pyridoxine deficiency 10.3 GPT SLC17A5

Graphical network of the top 20 diseases related to Viral Hepatitis:



Diseases related to Viral Hepatitis

Symptoms & Phenotypes for Viral Hepatitis

GenomeRNAi Phenotypes related to Viral Hepatitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.28 AFP ALB FAS FASLG FGL2 GGT1

MGI Mouse Phenotypes related to Viral Hepatitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.97 ABCB7 AFP ALB F2 FAS FASLG
2 digestive/alimentary MP:0005381 9.86 ALB F2 FAS FASLG HFE TLR2
3 liver/biliary system MP:0005370 9.61 ABCB7 AFP ALB FAS FASLG HFE
4 mortality/aging MP:0010768 9.47 ABCB7 AFP ALB F2 FAS FASLG

Drugs & Therapeutics for Viral Hepatitis

Drugs for Viral Hepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 283)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 198153-51-4 5360545
2
Peginterferon alfa-2b Approved Phase 4,Phase 2,Phase 3,Phase 1 99210-65-8, 215647-85-1
3
Ribavirin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 36791-04-5 37542
4
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142217-69-4 153941
5
Sofosbuvir Approved Phase 4,Phase 2,Phase 3 1190307-88-0 45375808
6
Efavirenz Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 154598-52-4 64139
7
Adefovir Dipivoxil Approved, Investigational Phase 4 142340-99-6 60871
8
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 134678-17-4 60825
9
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
10
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
11
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
12
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
13
Pravastatin Approved Phase 4 81093-37-0 54687
14
Simeprevir Approved Phase 4 923604-59-5 66576988
15
Milk thistle Approved, Experimental, Investigational Phase 4,Phase 2,Phase 3 65666-07-1
16
Maraviroc Approved, Investigational Phase 4,Phase 3,Phase 2 376348-65-1 3002977
17
Iron Approved Phase 4 7439-89-6 23925
18
Simvastatin Approved Phase 4 79902-63-9 54454
19
Zidovudine Approved Phase 4,Phase 3,Phase 2 30516-87-1 35370
20
Nevirapine Approved Phase 4,Phase 3,Phase 2 129618-40-2 4463
21
Ethambutol Approved Phase 4,Phase 2,Phase 3 74-55-5 3279 14052
22
Isoniazid Approved, Investigational Phase 4,Phase 3,Phase 2 54-85-3 3767
23
Emtricitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 143491-57-0 60877
24
Rifampicin Approved Phase 4,Phase 2,Phase 3 13292-46-1 5458213 5381226
25
Pyrazinamide Approved, Investigational Phase 4,Phase 2,Phase 3 98-96-4 1046
26
Ledipasvir Approved Phase 4,Phase 2 1256388-51-8 67505836
27
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 44475014
28
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
29
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
30
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2 50-14-6 5280793
31
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 1406-16-2
32
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 59-30-3 6037
33
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
34
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
35
Tenofovir Experimental, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 147127-20-6 464205
36
Adefovir Investigational Phase 4 106941-25-7
37
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
38
Cobalamin Experimental Phase 4 13408-78-1 6438156
39 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
40 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
41 Interferon-alpha Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
42 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
43 interferons Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
44 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
45 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Lipid Regulating Agents Phase 4,Phase 3,Phase 2
47 Atorvastatin Calcium Phase 4 134523-03-8
48 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
49 Calcium, Dietary Phase 4
50 Anticholesteremic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 382)
# Name Status NCT ID Phase Drugs
1 Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
2 Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4 entecavir (BARACLUDE®)
3 Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma Unknown status NCT02729506 Phase 4
4 Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine Unknown status NCT01548326 Phase 4 Atorvastatin;placebo
5 Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C Completed NCT00948220 Phase 4 peginterferon alfa-2a and ribavirin
6 Tenofovir vs. Tenofovir Plus Entecavir in Entecavir-Resistant Chronic Hepatitis B Completed NCT01639092 Phase 4 Tenofovir;Tenofovir;Entecavir
7 Tenofovir Plus Entecavir vs. Tenofovir in Adefovir-Resistant Chronic Hepatitis B Completed NCT01639066 Phase 4 Tenofovir;Entecavir;Tenofovir
8 A Randomized Controlled Trial of Lamivudine in Acute Hepatitis B Completed NCT00380614 Phase 4 Lamivudine
9 Interferon α 2b Pharmacovigilance Study Completed NCT01841775 Phase 4 interferon α 2b + ribavirin
10 Liver Function After Intravenous Methylprednisolone Administration Completed NCT03667157 Phase 4 every week IVMP therapy;very high doses IVMP therapy
11 Evaluation of 2 Interferon γ Assays in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT Completed NCT00647205 Phase 4
12 Rosuvastatin Versus Pravastatin in HIV Patients Treated With Boosted Protease Inhibitors (PI) (ANRS126) Completed NCT00117494 Phase 4 Pravastatin;Rosuvastatin
13 Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT) Completed NCT02624063 Phase 4 Daclatasvir + Sofosbuvir;Simeprevir + Sofosbuvir
14 Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice. Completed NCT01195181 Phase 4 peginterferon plus ribavirin
15 Efficacy of Silymarin for Acute Hepatitis Completed NCT00412763 Phase 4 Silymarin (Silybum marianum)
16 A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B Completed NCT01327547 Phase 4 Maraviroc;Placebo
17 Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3 Completed NCT00056862 Phase 4 Peginterferon alfa-2a;Peginterferon alfa-2a;Ribavirin
18 Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease Completed NCT00028093 Phase 4 Peginterferon alfa-2a with Ribavirin;Peginterferon alfa-2a
19 Long-Term Therapy With Ribavirin for Chronic Hepatitis C Completed NCT00001854 Phase 4 Ribavirin
20 Assessing the Role of "Statin" Therapy and Perioperative Inflammatory Response in Patients Undergoing Major Orthopedic Surgery Completed NCT00656292 Phase 4 Simvastatin;Placebo
21 Effectiveness Trial to Evaluate Protection of Pregnant Women by Hepatitis E Vaccine in Bangladesh. Recruiting NCT02759991 Phase 4 Hecolin;Hepa-B
22 HIV Diagnosis and Treatment at Birth for Newborn With High Risk HIV Exposure Recruiting NCT03642704 Phase 4 Reinforced preventive ARV therapy
23 Tenofovir As Prevention Of Hepatitis b Mother-to-child Transmission Recruiting NCT02937779 Phase 4 Tenofovir disoproxil fumarate
24 Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3 Active, not recruiting NCT02057796 Phase 4 ART (Atripla, Truvada, Efavirenz, Combivir);Rifampin, isoniazid, pyrazinamide, ethambutol
25 Strategic Timing of Antiretroviral Treatment Active, not recruiting NCT00867048 Phase 4 All licensed antiretroviral medications
26 DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C) Enrolling by invitation NCT03537196 Phase 4 Sofosbuvir 400 mg and Daclatasvir 60 mg;Sofosbuvir 400 mg and Daclatasvir 90 mg;Ribavirin;Sofosbuvir and Daclatasvir for 24 weeks
27 Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients Terminated NCT00122668 Phase 4 non-nucleoside reverse transcriptase inhibitors;nucleoside reverse transcriptase inhibitors;protease inhibitor
28 Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy Terminated NCT00122655 Phase 4 non-nucleoside reverse transcriptase inhibitors;nucleoside reverse transcriptase inhibitors;protease inhibitors
29 Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C Terminated NCT02120274 Phase 4 Vitamin D;Vitamin B 12
30 Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers Withdrawn NCT01766115 Phase 4 Telaprevir
31 Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients. Withdrawn NCT03279133 Phase 4 Ledipasvir 90mg/Sofosubvir 400mg
32 PEG-INTERFERON FOR INACTIVE HBV CARRIERS Unknown status NCT02992704 Phase 2, Phase 3 Peginterferon Alfa-2A
33 A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4 Unknown status NCT02371408 Phase 2, Phase 3 ravidasvir hydrochloride;sofosbuvir;ribavirin
34 Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa Unknown status NCT01715922 Phase 2, Phase 3 Fluconazole;Flucytosine
35 A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B Unknown status NCT01172392 Phase 3 Pegylated interferon-alpha-2a;Nucleotidic or Nucleosidic Treatment
36 BREATHER (PENTA 16) Short-Cycle Therapy (SCT) (5 Days on/2 Days Off) in Young People With Chronic HIV-infection Unknown status NCT01641016 Phase 2, Phase 3 efavirenz
37 Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C Completed NCT00265642 Phase 3 Irbesartan;placebo
38 Telbivudine Versus Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B Completed NCT01595685 Phase 3 Telbivudine;Entecavir
39 Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis Completed NCT00116454 Phase 3 131 I-lipiodol
40 The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient. Completed NCT01426243 Phase 3
41 Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients Completed NCT00946595 Phase 2, Phase 3 efavirenz/emtricitabin/tenofovir;lopinavir/ritonavir
42 Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices Completed NCT00657397 Phase 3 Methadone
43 Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding Completed NCT00640263 Phase 3 lopinavir/ritonavir (LPV/r);Lamivudine (3TC)
44 Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA) Completed NCT00573001 Phase 3 Tenofovir/Emtricitabine (Truvada) and Nevirapine;Tenofovir/Emtricitabine/Efavirenz (Atripla);Tenofovir (Viread) and Lopinavir/Ritonavir (Aluvia);Tenofovir/Emtricitabine (Truvada) and Zidovudine
45 Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO) Completed NCT00495651 Phase 3 Antiretroviral medications;Antiretroviral medications+Isoniazid prophylaxis;Antiretroviral medications;Antiretroviral medications+Isoniazid prophylaxis
46 Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO) Completed NCT00495326 Phase 2, Phase 3 Nevirapine based therapy;Efavirenz based therapy;Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)
47 Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load Completed NCT00454337 Phase 3 FTC/TDF + EFV or LPV/R +T20;FTC/TDF + EFV or LPV/R
48 Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136 Completed NCT00421551 Phase 3 Darunavir;ritonavir
49 Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients Completed NCT00391638 Phase 2, Phase 3 TRUVADA (EMTRICITABINE + TENOFOVIR DF)
50 Safety and Efficacy of Intradermal Injections of Newfill Versus Eutrophill in the Treatment of Facial Lipoatrophy in HIV-infected Patients ANRS 132 SMILE Completed NCT00383734 Phase 3

Search NIH Clinical Center for Viral Hepatitis

Cochrane evidence based reviews: hepatitis, viral, animal

Genetic Tests for Viral Hepatitis

Anatomical Context for Viral Hepatitis

MalaCards organs/tissues related to Viral Hepatitis:

41
Liver, Testes, T Cells, Kidney, Bone, Brain, Thyroid

Publications for Viral Hepatitis

Articles related to Viral Hepatitis:

(show top 50) (show all 1584)
# Title Authors Year
1
Creating demand for long-acting formulations for the treatment and prevention of HIV, tuberculosis, and viral hepatitis. ( 30394948 )
2019
2
Aiming at the Global Elimination of Viral Hepatitis: Challenges Along the Care Continuum. ( 29354656 )
2018
3
Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries. ( 29751763 )
2018
4
Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-I+ inhibitors in clinical practice. ( 29391775 )
2018
5
A Cross-Sectional Study of Viral Hepatitis Perception among Residents from Southeast and North Regions of Brazil. ( 29364166 )
2018
6
An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens. ( 29757684 )
2018
7
Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS). ( 29977962 )
2018
8
Impact of viral hepatitis B status on outcomes of intrahepatic cholangiocarcinoma: a meta-analysis. ( 29947010 )
2018
9
Psychological Disorders and Quality of Life Among Patients With Chronic Viral Hepatitis: A Single-Center Cross-Sectional Study With Pair-Matched Healthy Controls. ( 29847395 )
2018
10
Opisthorchiasis and viral hepatitis b: clinical cases. ( 29602941 )
2018
11
Clinical epidemiology of chronic viral hepatitis B: A Tuscany real-word large-scale cohort study. ( 29844854 )
2018
12
Focus on histological abnormalities of intrahepatic vasculature in chronic viral hepatitis. ( 29427537 )
2018
13
Epidemiology, Genotype Distribution, Prognosis, Control, and Management of Viral Hepatitis B, C, D, and Hepatocellular Carcinoma in Mongolia. ( 29963464 )
2018
14
Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals? ( 29443655 )
2018
15
Unravelling the fate of functional PD1+ T cells in chronic viral hepatitis. ( 29309052 )
2018
16
Viral hepatitis: Biomarker for HBV therapy discontinuation. ( 29362470 )
2018
17
Lumbar synovial cyst with chronic viral hepatitis: A case series and literature review. ( 29724648 )
2018
18
Incorporation of Social Determinants of Health in the Peer-Reviewed Literature: A Systematic Review of Articles Authored by the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. ( 29874147 )
2018
19
Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series. ( 29406396 )
2018
20
Epidemiological, demographic and clinical data on chronic viral hepatitis C in Tuscany. ( 29847179 )
2018
21
Safety of biologic agents for psoriasis in patients with viral hepatitis. ( 29345515 )
2018
22
Anti-infective potential of catechins and their derivatives against viral hepatitis. ( 29399578 )
2018
23
High burden of hepatocellular carcinoma and viral hepatitis in Southern and Central Vietnam: Experience of a large tertiary referral center, 2010 to 2016. ( 29399285 )
2018
24
Psoriatic patients with chronic viral hepatitis do not have an increased risk of liver cirrhosis despite long-term methotrexate use: real-world data from a nationwide cohort study in Taiwan. ( 29753054 )
2018
25
Association of viral hepatitis and bipolar disorder: a nationwide population-based study. ( 29929549 )
2018
26
Solid organ transplantation of viral hepatitis C positive donor organs into viral hepatitis C negative recipients. ( 29432255 )
2018
27
Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis. ( 29708985 )
2018
28
Comorbidity of viral hepatitis and chronic spontaneous urticaria: A systematic review. ( 29786879 )
2018
29
CROI 2018: Highlights of Viral Hepatitis. ( 29727295 )
2018
30
Management of chronic viral hepatitis in the hematological patient. ( 29415584 )
2018
31
IL-33 induces immunosuppressive neutrophils via a type 2 innate lymphoid cell/IL-13/STAT6 axis and protects the liver against injury in LCMV infection-induced viral hepatitis. ( 29400707 )
2018
32
Acute Viral Hepatitis: Beyond A, B, and C. ( 29751873 )
2018
33
Viral Hepatitis Recommendations for Solid-Organ Transplant Recipients and Donors. ( 29381580 )
2018
34
Comparison of Dynamic Changes Among Various Prognostic Scores in Viral Hepatitis-Related Acute Liver Failure. ( 29735790 )
2018
35
A study of association between regulatory polymorphism in the IL-10 gene promoter region and acute viral hepatitis, and acute liver failure. ( 30109600 )
2018
36
Complement System as a Target for Therapies to Control Liver Regeneration/Damage in Acute Liver Failure Induced by Viral Hepatitis. ( 30402508 )
2018
37
Viral Hepatitis and Acute Liver Failure: Still a Problem. ( 29605067 )
2018
38
Acute liver failure and misdiagnosis: Do not forget viral hepatitis E. ( 30017940 )
2018
39
Acute Exacerbation to Autoimmune Hepatitis Mimicking Acute Viral Hepatitis-A Case Series and Review of Literature. ( 29743801 )
2018
40
γδ T Cells Contribute to the Outcome of Murine Fulminant Viral Hepatitis via Effector Cytokines TNF-α and IFN-γ. ( 30128874 )
2018
41
Perforin inhibition protects from lethal endothelial damage during fulminant viral hepatitis. ( 30442932 )
2018
42
Guillain-Barré syndrome in a Child with Ongoing Viral Hepatitis A. ( 30026778 )
2018
43
Exploring the knowledge, attitudes and practices (KAP) of health care professionals on viral hepatitis notification in Gauteng, South Africa, 2015. ( 30555693 )
2018
44
Viral hepatitis, inflammation, and cancer: A lesson for autoimmunity. ( 30509387 )
2018
45
Ultrasonic assessment of liver stiffness and carotid artery elasticity in patients with chronic viral hepatitis. ( 30518330 )
2018
46
Erratum for McCarthy et al., "Identification of a Shared Cytochrome p4502E1 Epitope Found in Anesthetic Drug-Induced and Viral Hepatitis". ( 30518678 )
2018
47
Chronic Viral Hepatitis and Metabolic Syndrome/Cardiovascular Risk. ( 30519548 )
2018
48
Cross-sectional study to determine viral hepatitis knowledge in different urban populations in Brazil. ( 30533187 )
2018
49
Case finding and therapy for chronic viral hepatitis in primary care (HepFREE): a cluster-randomised controlled trial. ( 30477810 )
2018
50
Update on global epidemiology of viral hepatitis and preventive strategies. ( 30430114 )
2018

Variations for Viral Hepatitis

Expression for Viral Hepatitis

Search GEO for disease gene expression data for Viral Hepatitis.

Pathways for Viral Hepatitis

Pathways related to Viral Hepatitis according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.93 FAS FASLG IFNA1 IFNA2 TLR2 TNF
2
Show member pathways
12.85 FAS FASLG IFNA1 IFNA2 TLR2 TLR9
3
Show member pathways
12.82 FAS FASLG IFNA1 IFNA2 MX1 TLR2
4
Show member pathways
12.49 FAS FASLG TLR2 TLR9 TNF
5
Show member pathways
12.35 FAS FASLG IFNA1 IFNA2 TNF
6
Show member pathways
12.21 ALB F2 GGT1 TNF
7
Show member pathways
12.15 FAS FASLG KRT18 TNF
8 12.15 FAS FASLG TLR2 TNF
9 12.15 FAS FASLG IFNA1 TLR2 TLR9 TNF
10 12.11 FAS IFNA1 IFNA2 TLR2 TNF
11 12.02 IFNA1 IFNA2 TLR2 TLR9 TNF
12
Show member pathways
11.96 FAS FASLG IFNA1 IFNA2 TNF
13
Show member pathways
11.91 FAS FASLG IFNA1 IFNA2 MX1 TLR2
14
Show member pathways
11.87 FAS FASLG TLR2 TLR9 TNF
15 11.63 IFNA2 TLR9 TNF
16 11.42 FAS FASLG TNF
17 11.39 TLR2 TLR9 TNF
18 11.33 AFP ALB F2
19 11.31 FAS FASLG TNF
20 10.8 FAS FASLG TLR9 TNF

GO Terms for Viral Hepatitis

Cellular components related to Viral Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.81 ALB F2 FAS FASLG FGL2 GGT1
2 extracellular region GO:0005576 9.7 AFP ALB F2 FAS FASLG FGL2
3 endoplasmic reticulum lumen GO:0005788 9.62 AFP ALB F2 SERPINA1
4 membrane raft GO:0045121 9.56 FAS FASLG TLR2 TNF
5 extracellular space GO:0005615 9.36 AFP ALB F2 FASLG GGT1 GPT

Biological processes related to Viral Hepatitis according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.97 F2 FASLG IFNA1 IFNA2 TNF
2 cytokine-mediated signaling pathway GO:0019221 9.94 FASLG IFNA1 IFNA2 TNF
3 cellular protein metabolic process GO:0044267 9.88 AFP ALB F2 SERPINA1
4 blood coagulation GO:0007596 9.84 F2 IFNA1 IFNA2 SERPINA1
5 defense response to virus GO:0051607 9.81 IFNA1 IFNA2 MX1 TLR9
6 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.8 FAS FASLG TNF
7 immune response GO:0006955 9.8 FAS FASLG HFE TLR2 TLR9 TNF
8 positive regulation of inflammatory response GO:0050729 9.78 TLR2 TLR9 TNF
9 tumor necrosis factor-mediated signaling pathway GO:0033209 9.77 FASLG KRT18 TNF
10 type I interferon signaling pathway GO:0060337 9.74 IFNA1 IFNA2 MX1
11 apoptotic signaling pathway GO:0097190 9.73 FAS FASLG TNF
12 positive regulation of interleukin-6 production GO:0032755 9.72 TLR2 TLR9 TNF
13 defense response GO:0006952 9.71 IFNA1 IFNA2 MX1 TNF
14 humoral immune response GO:0006959 9.7 IFNA1 IFNA2 TNF
15 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.67 TLR2 TLR9 TNF
16 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.63 TLR2 TLR9
17 regulation of cytokine secretion GO:0050707 9.63 TLR2 TLR9
18 I-kappaB phosphorylation GO:0007252 9.62 TLR2 TLR9
19 response to molecule of bacterial origin GO:0002237 9.61 TLR2 TLR9
20 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.6 TLR9 TNF
21 acute-phase response GO:0006953 9.54 F2 HFE SERPINA1
22 positive regulation of interleukin-18 production GO:0032741 9.48 TLR2 TLR9
23 tumor necrosis factor production GO:0032640 9.46 TLR2 TLR9
24 positive regulation of toll-like receptor signaling pathway GO:0034123 9.43 TLR2 TLR9
25 positive regulation of interleukin-8 production GO:0032757 9.43 TLR2 TLR9 TNF
26 positive regulation of chemokine production GO:0032722 9.33 TLR2 TLR9 TNF
27 extrinsic apoptotic signaling pathway GO:0097191 9.26 FAS FASLG KRT18 TNF
28 necroptotic signaling pathway GO:0097527 8.8 FAS FASLG TNF

Molecular functions related to Viral Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling pattern recognition receptor activity GO:0008329 8.96 TLR2 TLR9
2 cytokine activity GO:0005125 8.92 FASLG IFNA1 IFNA2 TNF

Sources for Viral Hepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....